Drug Profile
Research programme: adjuvanted non-alum based anthrax vaccine - Altimmune
Alternative Names: Adjuvanted recombinant protective antigen anthrax vaccine - Altimmune; Adjuvanted rPA anthrax vaccine - Altimmune; DPX rPA vaccine - AltimmuneLatest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator PharmAthene
- Developer Altimmune
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Anthrax in USA (Parenteral)
- 04 May 2017 PharmAthene merged with Altimmune and the combined entity was renamed as Altimmune
- 15 Feb 2017 PharmAthene has patent protection for anthrax vaccine formulation and uses thereof in Europe (PharmAthene 10-K, March 2017)